U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07718243) titled 'Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC' on July 07.
Brief Summary: The trial will test if the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma. Early research suggests bexmarilimab may change some immune cells inside the tumour so they create a stronger "attack" signal, which could help other immune cells recognise and kill cancer cells more effectively. This may make it easier for PD-1 immunotherapy drugs to work again by helping ...